Astria Therapeutics, Inc. (ATXS)
- Previous Close
9.17 - Open
9.18 - Bid 8.95 x 200
- Ask 9.04 x 400
- Day's Range
8.97 - 9.46 - 52 Week Range
4.26 - 16.90 - Volume
1,099,020 - Avg. Volume
1,051,288 - Market Cap (intraday)
494.218M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-2.42 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.29
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
www.astriatx.comRecent News: ATXS
Performance Overview: ATXS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATXS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATXS
Valuation Measures
Market Cap
494.22M
Enterprise Value
343.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.06
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.47%
Return on Equity (ttm)
-31.40%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-72.89M
Diluted EPS (ttm)
-2.42
Balance Sheet and Cash Flow
Total Cash (mrq)
246.53M
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
-36.52M